GlobeNewswire

2024-10-28 17:51

Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities

Oct 28 PR

HYDERABAD, India, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India.

The General Good Manufacturing Practices (GMP) audit was conducted at the integrated R&D campus (Unit II) in April 2024, while the pre-approval inspection (PAI) & General GMP audit was conducted at the Manufacturing facility (Unit IV) in Bidar in June 2024.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said, “These audit outcomes reflect Sai Life Sciences’ commitment to maintaining the highest standards of quality and compliance across its R&D and manufacturing facilities. It demonstrates the company’s robust quality systems and its readiness to support the supply of high-quality pharmaceutical products to global markets."

[1] Among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR over FY22-24.

About Sai Life Sciences:

Sai Life Sciences is the fastest-growing contract research, development, and manufacturing organisation (CRDMO) among listed Indian peers (in terms of revenue CAGR as well as EBITDA CAGR from FY22 to FY24). As a pure-play, full-service CRDMO, we work with over 280 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes. Over the past 25 years, Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness. As of March 2024, we had 2845 employees across our facilities in India, UK, USA and Japan. https://www.sailife.com/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8a591e96-ed90-416a-b690-4cf120b64d12


For further information, contact:

Sriram Gopalakrishnan
Vice President, Corporate Communication
Sai Life Sciences Limited
Ph: +91 9121295355
sriram.g@sailife.com

Primary Logo

source: SAI LIFE SCIENCES LIMITED

【你點睇?】南韓總統突然宣布戒嚴,戒嚴令僅持續6個多小時,你認為事件會否加劇朝鮮半島不穩定局勢?► 立即投票

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet30周年連環賞】睇住賞睇住賞Maxcare美天膝健寶(價值HK$2,699)

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

Watche Trends 2024

北上食買玩

Art Month 2024

理財秘笈

秋天養生食療

消委會報告

山今養生智慧

輕鬆護老